Best Practice & Research Clinical Rheumatology
Volume 23, Issue 1 , Pages 49-58 , February 2009

The preclinical stages of RA: lessons from human studies and animal models

  • Hani El-Gabalawy, MD, FRCPC (Professor of Medicine and Immunology)

      Affiliations

    • Corresponding Author InformationTel.: +1 204 787 2208.

References 

  1. Nielen MM, van SD, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380–386
  2. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741–2749
  3. Majka DS, Deane KD, Parrish LA, et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis. 2008;67(6):801–807
  4. Aho K, Palosuo T, Raunio V, et al. When does rheumatoid disease start?. Arthritis Rheum. 1985;28(5):485–489
  5. mjadi-Begvand S, Khanna D, Park GS, et al. Dating the ‘window of therapeutic opportunity’ in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset. J Rheumatol. 2004;31(9):1686–1692
  6. Cush JJ. Early rheumatoid arthritis – is there a window of opportunity?. J Rheumatol. Supplement. 2007;80:1–7
  7. Aho K, Heliovaara M, Maatela J, et al. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol. 1991;18(9):1282–1284
  8. Aho K, von ER, Kurki P, et al. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol. 1993;20(8):1278–1281
  9. Aho K, Palosuo T, Heliovaara M, et al. Antifilaggrin antibodies within ‘normal’ range predict rheumatoid arthritis in a linear fashion. J Rheumatol. 2000;27(12):2743–2746
  10. Kurki P, Aho K, Palosuo T, Heliovaara M. Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis Rheum. 1992;35(8):914–917
  11. Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101(1):273–281
  12. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol. 2001;166(6):4177–4184
  13. Rantapaa-Dahlqvist S, Boman K, Tarkowski A, Hallmans G. Up regulation of monocyte chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin M rheumatoid factor positive subjects precedes onset of inflammatory response and development of overt rheumatoid arthritis. Ann Rheum Dis. 2007;66(1):121–123
  14. Berglin E, Padyukov L, Sundin U, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther. 2004;6(4):R303–R308
  15. Huizinga TW, Amos CI, van der Helm-van Mil AH, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 2005;52(11):3433–3438
  16. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum. 2006;54(4):1117–1121
  17. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38–46
  18. Johansson M, Arlestig L, Hallmans G, Rantapaa-Dahlqvist S. PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res Ther. 2006;8(1):R19
  19. Harrison P, Pointon JJ, Farrar C, et al. Effects of PTPN22 C1858T polymorphism on susceptibility and clinical characteristics of British Caucasian rheumatoid arthritis patients. Rheumatology (Oxford). 2006;45(8):1009–1011
  20. Plenge RM, Padyukov L, Remmers EF, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet. 2005;77(6):1044–1060
  21. van OM, Wintle RF, Liu X, et al. Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations. Arthritis Rheum. 2005;52(7):1993–1998
  22. Hinks A, Barton A, John S, et al. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum. 2005;52(6):1694–1699
  23. Lee AT, Li W, Liew A, et al. The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status. Genes Immun. 2005;6(2):129–133
  24. Begovich AB, Carlton VE, Honigberg LA, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet. 2004;75(2):330–337
  25. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007;357(10):977–986
  26. Rodriguez MR, Nunez-Roldan A, Aguilar F, et al. Association of the CTLA4 3' untranslated region polymorphism with the susceptibility to rheumatoid arthritis. Hum Immunol. 2002;63(1):76–81
  27. Suzuki A, Yamada R, Chang X, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet. 2003;34(4):395–402
  28. Plenge RM, Seielstad M, Padyukov L, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis–a genomewide study. N Engl J Med. 2007;357(12):1199–1209
  29. Heliovaara M, Aho K, Aromaa A, et al. Smoking and risk of rheumatoid arthritis. J Rheumatol. 1993;20(11):1830–1835
  30. Silman AJ, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum. 1996;39(5):732–735
  31. Stolt P, Bengtsson C, Nordmark B, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis. 2003;62(9):835–841
  32. Pedersen M, Jacobsen S, Garred P, et al. Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum. 2007;56(5):1446–1453
  33. van der Helm-van Mil AH, Verpoort KN, le CS, et al. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum. 2007;56(2):425–432
  34. Lorentzen JC, Glaser A, Jacobsson L, et al. Identification of rat susceptibility loci for adjuvant-oil-induced arthritis. Proc Natl Acad Sci U S A. 1998;95(11):6383–6387
  35. Vingsbo C, Sahlstrand P, Brun JG, et al. Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. Am J Pathol. 1996;149(5):1675–1683
  36. Sverdrup B, Kallberg H, Bengtsson C, et al. Association between occupational exposure to mineral oil and rheumatoid arthritis: results from the Swedish EIRA case-control study. Arthritis Res Ther. 2005;7(6):R1296–R1303
  37. Rosenstein ED, Greenwald RA, Kushner LJ, Weissmann G. Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. Inflammation. 2004;28(6):311–318
  38. de PP, Dietrich T, McAlindon TE. Association of periodontal disease and tooth loss with rheumatoid arthritis in the US population. J Rheumatol. 2008;35(1):70–76
  39. Harris ML, Darrah E, Lam GK, et al. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum. 2008;58(7):1958–1967
  40. Kinloch A, Tatzer V, Wait R, et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther. 2005;7(6):R1421–R1429
  41. Kinloch A, Lundberg K, Wait R, et al. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum. 2008;58(8):2287–2295
  42. Cho YG, Cho ML, Min SY, Kim HY. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev. 2007;7(1):65–70
  43. Nandakumar KS, Holmdahl R. Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. J Immunol Methods. 2005;304(1–2):126–136
  44. Kuhn KA, Kulik L, Tomooka B, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest. 2006;116(4):961–973
  45. von DA, Altmann DM, Isaacs JD, et al. The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model. Arthritis Rheum. 2006;54(2):482–491
  46. Matsumoto I, Staub A, Benoist C, Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science. 1999;286(5445):1732–1735
  47. Matsumoto I, Maccioni M, Lee DM, et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol. 2002;3(4):360–365
  48. Ji H, Pettit A, Ohmura K, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med. 2002;196(1):77–85
  49. Monach PA, Verschoor A, Jacobs JP, et al. Circulating C3 is necessary and sufficient for induction of autoantibody-mediated arthritis in a mouse model. Arthritis Rheum. 2007;56(9):2968–2974
  50. Ji H, Ohmura K, Mahmood U, et al. Arthritis critically dependent on innate immune system players. Immunity. 2002;16(2):157–168
  51. Nigrovic PA, Binstadt BA, Monach PA, et al. Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. Proc Natl Acad Sci U S A. 2007;104(7):2325–2330
  52. Lee DM, Friend DS, Gurish MF, et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002;297(5587):1689–1692
  53. Schaller M, Burton DR, Ditzel HJ. Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat Immunol. 2001;2(8):746–753
  54. Kassahn D, Kolb C, Solomon S, et al. Few human autoimmune sera detect GPI. Nat Immunol. 2002;3(5):411–412
  55. Matsumoto I, Lee DM, Goldbach-Mansky R, et al. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum. 2003;48(4):944–954
  56. Hill JA, Southwood S, Sette A, et al. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol. 2003;171(2):538–541
  57. Hill JA, Bell DA, Brintnell W, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med. 2008;205(4):967–979
  58. Ioan-Facsinay A, Willemze A, Robinson D, et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum. 2008;58(10):3000–3008
  59. Li W, Wang M, Irigoyen P, Gregersen PK. Inferring causal relationships among intermediate phenotypes and biomarkers: a case study of rheumatoid arthritis. Bioinformatics. 2006;22(12):1503–1507
  60. Wipke BT, Wang Z, Nagengast W, et al. Staging the initiation of autoantibody-induced arthritis: a critical role for immune complexes. J Immunol. 2004;172(12):7694–7702
  61. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, et al. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum. 2006;54(12):3799–3808
  62. Boire G, Cossette P, de Brum-Fernandes AJ, et al. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther. 2005;7(3):R592–R603
  63. Willemze A, Ioan-Facsinay A, El-Gabalawy HS. Evolution of Anti-Citrullinated Protein Antibody (ACPA) response is associated with synovial immune deposits in a patient with suspected early rheumatoid arthritis. J Rheumatol. 2008;35(11):2282–2284
  64. Masson-Bessiere C, Sebbag M, Durieux JJ, et al. In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol. 2000;119(3):544–552
  65. Reparon-Schuijt CC, van Esch WJ, van KC, et al. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum. 2001;44(1):41–47
  66. Ireland J, Herzog J, Unanue ER. Cutting edge: unique T cells that recognize citrullinated peptides are a feature of protein immunization. J Immunol. 2006;177(3):1421–1425

PII: S1521-6942(08)00133-2

doi: 10.1016/j.berh.2008.11.004

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 1 , Pages 49-58 , February 2009

Article Tools

* Image Usage & Resolution